Poolbeg Pharma PLC (POLBF)
OTCMKTS · Delayed Price · Currency is USD
0.0420
-0.0760 (-64.41%)
At close: May 22, 2025

Poolbeg Pharma Income Statement

Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
5.263.383.062.71
Research & Development
1.381.682.20.55
Other Operating Expenses
-0.53-0.37-0.28-0.15
Operating Expenses
6.114.694.993.11
Operating Income
-6.11-4.69-4.99-3.11
Interest & Investment Income
0.430.530.21-
EBT Excluding Unusual Items
-5.68-4.15-4.78-3.11
Gain (Loss) on Sale of Assets
-0.26---
Asset Writedown
--0.35--
Pretax Income
-5.94-4.51-4.78-3.11
Income Tax Expense
-0.15-0.57-0.09-
Net Income
-5.79-3.93-4.69-3.11
Net Income to Common
-5.79-3.93-4.69-3.11
Shares Outstanding (Basic)
500500500317
Shares Outstanding (Diluted)
500500500317
Shares Change (YoY)
--57.62%-
EPS (Basic)
-0.01-0.01-0.01-0.01
EPS (Diluted)
-0.01-0.01-0.01-0.01
EBITDA
-6-4.66-4.96-3.09
D&A For EBITDA
0.110.030.030.02
EBIT
-6.11-4.69-4.99-3.11
Source: S&P Global Market Intelligence. Standard template. Financial Sources.